Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Biliary02: Rilvegostomig + chemotherapy vs Durvalumab + chemotherapy in advanced biliary tract cancer
2025-523085-24-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of rilvegostomig in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Planned start Mar 2026; status: authorised.
02
Drugs
rilvegostomig
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2025-523085-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523085-24-00.